Locations
Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), St. AugustineCondition
Heart DiseaseOlpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) – Outcomes Trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
clinicaltrials.govEligibility
Inclusion Criteria
- Age 18 to ≤ 85 years
- Lp(a) ≥ 200 nmol/L during screening
- History of ASCVD as evidenced by history of either:
- Myocardial infarction and/or
- Coronary revascularization with percutaneous coronary intervention with stenting AND at least 1 additional risk factor
Exclusion Criteria
- Severe renal dysfunction
- Active liver disease, known hepatitis, or hepatic dysfunction
- History of hemorrhagic stroke
- History of major bleeding disorder
- Planned cardiac surgery or arterial revascularization
- Severe heart failure
- Current, recent, or planned lipoprotein apheresis
- Previously received ribonucleic acid therapy specifically targeting Lp(a)